CD8A and neoplasm: The neoepitope IGPRALDVL, which elicited intermediate tumor rejection (Figure 2A) and a good CD8+ T cell response in naive mice (Figure 2F), elicited a significant CD8+ T cell response in tumor-bearing mice as well (Figure 2F).